### 各MTAの最後の条文

* **UK Biobank (mta_ukbb_7-9.md):** 9.6 The Applicant shall not process any Participant Level Data (nor permit any Participant Level Data to be processed) in a territory outside of the UK (or where clause 9.4 applies, where processing occurs in a subsequent territory) unless it has taken such measures as are necessary to ensure the transfer is in compliance with Data Protection Legislation.
* **European Genome-phenome Archive (mta_ega.md):** 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.
* **NIH (mta_nih.md):** EXHIBIT A Data

***

### UK Biobank (UKBB)の条文と対応するEGAおよびNIHの条文

* **UKBBの条文（英）:** 7.1 During the Term, UK Biobank requires the Applicant Pl to confirm on an annual basis that the Approved Research Project remains compliant with the provisions of the MTA (and the Annexes). Specifically, the Applicant PI shall provide UK Biobank with such confirmation as part of the Annual Project Report in the form attached at Annex 3. In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, UK Biobank reserves the rights set out in clause 5.5 above.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 7.2 In circumstances where UK Biobank reasonably believes that a Data Security Incident or other serious incident has occurred then, on notice to the Applicant, in order to confirm or investigate compliance with the provisions of this MTA, UK Biobank may itself or via appropriate third parties:
        * 7.2.1 choose to undertake an audit (either in person or remotely) in order to review the security, storage or other arrangements for the Materials; and
        * 7.2.2 request such additional information about the Approved Research Project and/or its progress as UK Biobank may, from time to time, reasonably require.
    * **対応するEGAの条文（英）:** 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement.
        * **比較結果:** 部分一致
        * **判断理由（日）:** UKBBは、データセキュリティインシデントが発生した場合に監査を実施できると具体的に述べている。EGAは、要求された場合にデータセキュリティ文書の検査を許可することに言及している。どちらも監査について言及しているが、UKBBはより詳細な状況と方法を規定しているため、部分一致とした。
    * **対応するNIHの条文（英）:** 1.h. Registry (or its agents) may audit Researcher's use of the Data to ensure compliance with this Agreement. Any such audits will be conducted during Researcher's regular business hours with reasonable advanced notice and consideration for Researcher's business operations. Researcher will cooperate, and will ensure that all Researcher personnel will cooperate, with the auditors and will make all records and materials available to them.
        * **比較結果:** 一致
        * **判断理由（日）:** UKBBとNIHの両方の条文は、データ提供者が遵守を確保するために、研究者のデータの使用を監査する権利を持っていることを定めているため、一致とした。

* **UKBBの条文（英）:** 7.3 UK Biobank shall bear the costs of such audits unless a material default within the procedures and processes of the relevant Applicant is discovered, in which case the relevant Applicant shall be obliged to reimburse the reasonable costs of UK Biobank and any relevant third parties.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 7.4 UK Biobank confirms that its audit rights shall be exercisable no more than once a year and on the provision of reasonable notice (which may be immediate in the event of a Data Security Incident or other serious incident) to the Applicant. As far as practically possible, UK Biobank agrees to coordinate any site visits and audits with the other relevant parties.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 8.1 Subject to the exceptions in clause 8.2, UK Biobank shall keep confidential any information disclosed to it in writing by the Applicant that is marked confidential ("Applicant's Confidential Information") and shall not disclose such information to any person.
    * **対応するEGAの条文（英）:** 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data.
        * **比較結果:** 部分一致
        * **判断理由（日）:** UKBBはUK Biobankが申請者の機密情報を保護することについて述べているのに対し、EGAはユーザー機関がデータ自体の機密性を保護することに焦点を当てているため、部分一致とした。
    * **対応するNIHの条文（英）:** 7.b. Researcher agrees that it will not disclose to others or use for its own benefit or the benefit of others, any Data or other Confidential Information disclosed by Registry in the course of this Agreement. For purposes of this Agreement, "Confidential Information" shall mean methods, processes, know-how, policies, procedures, templates, and other non-public confidential information of Registry. All Confidential Information is and shall remain the confidential property of Registry. Researcher shall keep the Confidential Information in strict confidence and may not use or otherwise disclose the Confidential Information to any third party without the prior written consent of Registry.
        * **比較結果:** 部分一致
        * **判断理由（日）:** UKBBはUK Biobankが申請者の機密情報を保護することに焦点を当てている。一方、NIHは研究者がレジストリの機密情報を保護する義務を規定しており、対象となる情報が異なるため、部分一致とした。

* **UKBBの条文（英）:** 8.2 UK Biobank may disclose the Applicant's Confidential Information where expressly permitted by this MTA or when:
        * 8.2.1 it is required to be disclosed by law, by any governmental or other regulatory authority, by a court or other authority of competent jurisdiction; or
        * 8.2.2 it can be shown by UK Biobank (to the Applicant's reasonable satisfaction) to have been known by UK Biobank before disclosure to it by such Applicant; or
        * 8.2.3 it was lawfully disclosed to UK Biobank by a third party who did not impose any restrictions on its disclosure; or
        * 8.2.4 the information was in (or enters into) the public domain other than by reason of a breach of this clause by UK Biobank; or
        * 8.2.5 UK Biobank and the Applicant agree, acting reasonably, that such information is trivial or obvious, or they agree in writing that such disclosure may be permitted.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 9.1 The parties acknowledge that UK Biobank and the Applicant are independent controllers with respect to the Participant Level Data that is processed in accordance with this MTA, and that the Applicant shall process the Participant Level Data strictly for the Permitted Purpose. In no event shall the parties process the Participant Level Data as joint controllers.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 9.2 Each party shall be individually and separately responsible for complying with the obligations that apply to it as a controller under Data Protection Legislation.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 9.3 In the event that the Applicant, Applicant PI or any Applicant Researcher receives any correspondence, enquiry or complaint from a Participant, regulator or other third party ("Correspondence") in connection with the processing of the Participant Level Data, it shall promptly inform UK Biobank giving full details of the same. In all circumstances, the Applicant, Applicant PI or any Applicant Researcher shall: (i) obtain UK Biobank's written approval before responding to the Correspondence, including approval of the contents of any response; and (ii) subject to Data Protection Legislation, permit UK Biobank to respond directly to the Correspondence.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 9.4 Where UK Biobank transfers Participant Level Data to an Applicant outside the UK to a territory that has not been specified as ensuring an adequate level of protection in accordance with Data Protection Legislation, the parties agree that the UK Addendum shall be automatically incorporated into this MTA by reference and deemed to be completed as set out in Part B of Annex 1 of this MTA.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 9.5 If there is any conflict between the MTA and the UK Addendum, the UK Addendum will prevail.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

* **UKBBの条文（英）:** 9.6 The Applicant shall not process any Participant Level Data (nor permit any Participant Level Data to be processed) in a territory outside of the UK (or where clause 9.4 applies, where processing occurs in a subsequent territory) unless it has taken such measures as are necessary to ensure the transfer is in compliance with Data Protection Legislation.
    * **対応するEGAの条文（英）:** なし
    * **対応するNIHの条文（英）:** なし

***

### 条文番号の対応関係

| UKBBの条文番号 | EGAの条文番号 | NIHの条文番号 |
| :--- | :--- | :--- |
| 7.1 | なし | なし |
| 7.2 | 17 | 1.h |
| 7.3 | なし | なし |
| 7.4 | なし | なし |
| 8.1 | 2 | 7.b |
| 8.2 | なし | なし |
| 9.1 | なし | なし |
| 9.2 | なし | なし |
| 9.3 | なし | なし |
| 9.4 | なし | なし |
| 9.5 | なし | なし |
| 9.6 | なし | なし |